178 related articles for article (PubMed ID: 34330018)
21. Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.
Yaccoby S; Pennisi A; Li X; Dillon SR; Zhan F; Barlogie B; Shaughnessy JD
Leukemia; 2008 Feb; 22(2):406-13. PubMed ID: 18046446
[TBL] [Abstract][Full Text] [Related]
22. Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS.
Shen X; Dong X; Shi J; Chen H; Lan Y; Lim AC; Xie F; Ang A; Kratzer A; Rock DA; Rock BM
Clin Chem; 2024 Jan; 70(1):339-349. PubMed ID: 38175591
[TBL] [Abstract][Full Text] [Related]
23. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.
Li D; Que Y; Ding S; Hu G; Wang W; Mao X; Wang Y; Li C; Huang L; Zhou J; Zhang W; Xiao M
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36137648
[TBL] [Abstract][Full Text] [Related]
24. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
[TBL] [Abstract][Full Text] [Related]
25. γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
Chen H; Yu T; Lin L; Xing L; Cho SF; Wen K; Aardalen K; Oka A; Lam J; Daley M; Lu H; Munshi N; Anderson KC; Tai YT
Blood Cancer J; 2022 Aug; 12(8):118. PubMed ID: 35973981
[TBL] [Abstract][Full Text] [Related]
26. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
27. [Role of B-cell-activating-factor in immune regulation--review].
Du JF; Wang JX; Xu DG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):631-4. PubMed ID: 16800959
[TBL] [Abstract][Full Text] [Related]
28. [Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus].
Valor L; López-Longo FJ
Med Clin (Barc); 2015 Sep; 145(5):206-10. PubMed ID: 25433780
[TBL] [Abstract][Full Text] [Related]
29. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Novak AJ; Darce JR; Arendt BK; Harder B; Henderson K; Kindsvogel W; Gross JA; Greipp PR; Jelinek DF
Blood; 2004 Jan; 103(2):689-94. PubMed ID: 14512299
[TBL] [Abstract][Full Text] [Related]
30. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
31. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
32. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.
Becerra E; De La Torre I; Leandro MJ; Cambridge G
Clin Exp Immunol; 2017 Dec; 190(3):372-383. PubMed ID: 28800164
[TBL] [Abstract][Full Text] [Related]
33. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
Alomari M; Kunacheewa C; Manasanch EE
Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
[TBL] [Abstract][Full Text] [Related]
34. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
Endo T; Nishio M; Enzler T; Cottam HB; Fukuda T; James DF; Karin M; Kipps TJ
Blood; 2007 Jan; 109(2):703-10. PubMed ID: 16973958
[TBL] [Abstract][Full Text] [Related]
35. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
36. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
[TBL] [Abstract][Full Text] [Related]
37. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Demel I; Bago JR; Hajek R; Jelinek T
Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
[TBL] [Abstract][Full Text] [Related]
38. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV
Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455
[TBL] [Abstract][Full Text] [Related]
39. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.
Chiu A; Xu W; He B; Dillon SR; Gross JA; Sievers E; Qiao X; Santini P; Hyjek E; Lee JW; Cesarman E; Chadburn A; Knowles DM; Cerutti A
Blood; 2007 Jan; 109(2):729-39. PubMed ID: 16960154
[TBL] [Abstract][Full Text] [Related]
40. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
